Quantitative evaluation of T2-mapping relaxation times shows significant differences regarding the IDH-status in WHO grade II and III gliomas as IDH-mut gliomas have a higher T2 SI, adding important information regarding the new 2016 World Health Organization (WHO) Classification of tumors of the central nervous system. The gene discussed is IDH2; the disease is central nervous system cancer.